These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34594940)

  • 21. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of live attenuated herpes zoster vaccine in Australian adults 70-79 years of age: an observational study using active surveillance.
    Phillips A; Glover C; Leeb A; Cashman P; Fathima P; Crawford N; Snelling TL; Durrheim D; Macartney K
    BMJ Open; 2021 Mar; 11(3):e043880. PubMed ID: 33766842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance.
    Wu L; Yang S; Huang Z; Liu J; Guo X; Bai Q; Sun X
    Vaccine; 2023 Mar; 41(14):2412-2417. PubMed ID: 36872142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008-2013.
    Wu W; Liu D; Li K; Nuorti JP; Nohynek HM; Xu D; Ye J; Zheng J; Wang H
    Vaccine; 2017 Jun; 35(29):3666-3671. PubMed ID: 28552510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Data collection systems for active safety surveillance of vaccines during pregnancy in low- and middle-income countries: developing and piloting an assessment tool (VPASS).
    Belizán M; Rodriguez Cairoli F; Mazzoni A; Goucher E; Zaraa S; Matthews S; Pingray V; Stergachis A; Xiong X; Berrueta M; Buekens P
    BMC Pregnancy Childbirth; 2023 Mar; 23(1):172. PubMed ID: 36915061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group.
    Chandler RE; Balakrishnan MR; Brasseur D; Bryan P; Espie E; Hartmann K; Jouquelet-Royer C; Milligan J; Nesbitt L; Pal S; Precioso A; Takey P; Chen RT;
    BMJ Glob Health; 2024 Mar; 9(3):. PubMed ID: 38453518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety analysis of a live attenuated mumps vaccine in healthy adolescents in China: A phase 4, observational, open-label trial.
    Hu W; Jia N; Meng W; Zhou T; Wang R; Xiong Y; Luan C; Zhang S
    PLoS One; 2023; 18(9):e0291730. PubMed ID: 37733724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.
    Guo B; Page A; Wang H; Taylor R; McIntyre P
    Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.
    Lei J; Balakrishnan MR; Gidudu JF; Zuber PLF
    Vaccine; 2018 Mar; 36(12):1577-1582. PubMed ID: 29454518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India.
    John J; Kawade A; Rongsen-Chandola T; Bavdekar A; Bhandari N; Taneja S; Antony K; Bhatnagar V; Gupta A; Kabra M; Kang G
    Vaccine; 2014 Aug; 32 Suppl 1():A104-9. PubMed ID: 25091662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance of adverse events following immunization in China: Past, present, and future.
    Liu D; Wu W; Li K; Xu D; Ye J; Li L; Wang H
    Vaccine; 2015 Jul; 33(32):4041-6. PubMed ID: 25936727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe.
    Shaum A; Mujuru HA; Takamiya M; Ticklay I; Nathoo K; Sreenivasan N; Nyambayo P; Chitando P; Marembo J; Koline Chigodo C; Mukaratirwa A; Jacha V; Gidudu JF; Rupfutse M; Kumar Jain S; Manangazira P; Bennett SD
    Vaccine; 2022 Jun; 40(26):3573-3580. PubMed ID: 35568590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Planning for COVID-19 vaccines safety surveillance.
    Kochhar S; Salmon DA
    Vaccine; 2020 Sep; 38(40):6194-6198. PubMed ID: 32684499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From program suspension to the pandemic: A qualitative examination of Australia's vaccine pharmacovigilance system over 10 years.
    Phillips A; Carlson S; Danchin M; Beard F; Macartney K
    Vaccine; 2021 Sep; 39(40):5968-5981. PubMed ID: 34376308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
    Nguyen M; Ball R; Midthun K; Lieu TA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine safety in Australia during the COVID-19 pandemic: Lessons learned on the frontline.
    Laemmle-Ruff I; Lewis G; Clothier HJ; Dimaguila GL; Wolthuizen M; Buttery J; Crawford NW
    Front Public Health; 2022; 10():1053637. PubMed ID: 36408022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Strengthen the studies on vaccine safety surveillance and economic assessment in China: not a moment too soon].
    Zhang J
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):661-663. PubMed ID: 31288334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.
    Pan X; Lv H; Chen F; Wang Y; Liang H; Shen L; Chen Y; Hu Y
    Hum Vaccin Immunother; 2021 Oct; 17(10):3823-3830. PubMed ID: 34170800
    [No Abstract]   [Full Text] [Related]  

  • 40. Change in adverse event reporting following immunization of hepatitis B vaccine among infants between 2013 to 2020 before and after the vaccine administration law in China.
    Wang C; Huang N; Lu QB; Black S; Liang X; Cui F
    Front Immunol; 2022; 13():956473. PubMed ID: 36248783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.